主要从事基于生物靶标结构及作用机制的创新药物研究。重点以未满足临床需求的新型抗病毒药物发现为切入点，基于药物作用靶标三维结构、作用机制或新颖类药性优势骨架，系统开展新型小分子药物设计及与生物大分子之间相互作用规律研究，同时基于类药性优势骨架开展先导化合物的高效合成和结构优化，为创新药物研发提供活性化合物；
Wang Y#, Xie B#, Deng X, Dong C*, Zhou HB*. Targeted Degradation of the Estrogen Receptor α through Unconventional Coactivator Binding Site (CBS) (6.8). J. Med. Chem., 2025 Jun 17;68(13), 13640-13660. DOI: 10.1021/acs.jmedchem.5c00495
Liang J#, Wang D#, Wu Y#, Shi J, Xie B, Xiao R, Ni J, Wang C, Dong C, Shu HB*, Li S*, Zhou HB*. Intercepting the Downstream of the Estrogen Receptor Signaling Pathway: Discovery of a Potent and Efficient SRC-3 PROTAC Degrader for Overcoming Endocrine Resistance Breast Cancer (6.8). J. Med. Chem., 2025 May 28;68(11), 11516-11542. DOI: 10.1021/acs.jmedchem.5c00425
Song Z#, Cui Y#, Xin L, Xiao R, Feng J, Li C, Yin Z, Wang H, Li Q, Wang M, Lin B, Zhang Y, Zhou Y, Huang L, He Y, Li X, Liu X, Liu S, Zhou F, Liu Z, Zhou HB*, Fang P*, Liang K*. Mechano-oncogenic cytoskeletal remodeling drives leukemic transformation with mitochondrial vesicle-mediated STING activation (19.8). Cell Stem Cell 2025 Apr 3;32(4), 581-597. DOI: 10.1016/j.stem.2025.01.013
Xin L#, Wang C#, Cheng Y#, Wang H, Guo X, Deng X, Deng X, Xie B, Hu H, Min C, Dong C*, Zhou HB*. Discovery of Novel ERα and Aromatase Dual-Targeting PROTAC Degraders to Overcome Endocrine-Resistant Breast Cancer (6.8). J. Med. Chem., 2024 May 29;67(11), 8913–8931. DOI10.1021/acs.jmedchem.4c00196
Ma X#, Wang X#, Chen F#, Zou W#, Ren J, Xin L, He P, Liang J, Xu Z, Dong C, Lan K*, Wu S*, Zhou HB*. Novel Acyl Thiourea-Based Hydrophobic Tagging Degraders Exert Potent Anti-Influenza Activity through Two Distinct Endonuclease Polymerase Acidic-Targeted Degradation Pathways (6.8). J. Med. Chem., 2024 May 22;67(11), 8791–8816. DOI: 10.1021/acs.jmedchem.4c00131
Tan Y#, Xin L#, Wang Q, Xu R, Tong X, Chen G, Ma L, Yang F, Jiang H, Zhang N, Wu J, Li X, Guo X, Wang C, Zhou HB*, Zhou F*. FLT3-Selective PROTAC: Enhanced Safety and Increased Synergy with Venetoclax in FLT3-ITD Mutated Acute Myeloid Leukemia Author links open overlay panel (9.1). Cancer Letters 2024 Jun 28;592, 216933. DOI:10.1016/j.canlet.2024.216933
Wang Y#, Min J#, Deng X#, Feng T#, Hu H, Guo X, Cheng Y, Xie B, Yang Y, Chen CC, Guo RT*, Dong C*, Zhou HB*. Discovery of novel covalent selective estrogen receptor degraders against endocrine-resistant breast cancer (IF: 14.4). Acta Pharmaceutica Sinica B 2023 Dec 2023;13(12), 4963-4982. DOI: 10.1016/j.apsb.2023.05.005
Deng X#, Deng X#, Ning W#, Xin L#, Li Q, Hu Z, Xie B, Liang K, Min C, Dong C*, Huang J*, Zhou HB*. Identification of Novel Dual-Target Estrogen Receptor α Degraders with Tubulin Inhibitory Activity for the Treatment of Endocrine-Resistant Breast Cancer (7.3). J. Med. Chem., 2023 Aug 24;66(16), 11094-11117. DOI: 10.1021/acs.jmedchem.3c00465
Liu XJ#, Xu Z#, Liang J#, Yu L, Ren P, Zhou HB*, Wu S*, Lan K*. Identification of a novel acylthiourea-based potent broad-spectrum inhibitor for enterovirus 3D polymerase in vitro and in vivo (7.6). Antiviral Research 2023 May;213, 105583. DOI: 10.1016/j.antiviral.2023.105583
Liu X#, Liang J#, Yu Y#, Han X, Yu L, Chen F, Xu Z, Chen Q, Jin M, Dong C, Zhou HB*, Lan K*, Wu S*. Discovery of Aryl Benzoyl Hydrazide Derivatives as Novel Potent Broad-Spectrum Inhibitors of Influenza A Virus RNA Dependent RNA Polymerase (RdRp) (7.3). J. Med. Chem., 2022 Mar 10;65(5), 3814–3832. DOI: 10.1021/acs.jmedchem.1c01257
